SBIR/STTR Research Award
IGF OT IGF SBIR PHASE II TOPIC DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS
Award amount
$1,496,276Program and phase
SBIR · Phase IIAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Cellerant Therapeutics, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LML1YE6L8KU3
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
The effectiveness of current AML treatments is abysmal yielding only an overall year survival rate of and it has been hypothesized that the treatment may be more durable if leukemic stem cells LSC are eliminated IL RAP is a compelling target because it is expressed on LSC in majority of AML patients but not on healthy hematopoietic stem cells Also suppressing IL RAP expression in AML cells can greatly inhibit tumor cell growth survival From SBIR Phase I contract the contractor developed various antibodies against IL RAP having functional blocking properties a higher affinity for membrane bound IL RAP relative to the secreted form and tumor cell inhibition activities
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation
- OTHER FUNCTION: Development of IL1RAP antibodies targeting AML CS
- Novel indication for myeloid progenitor use: Induction of tolerance
- IGF::OT::IGF OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)
- Attenuation of Radiation-Induced GI Injury by Cultured Myeloid Progenitors
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
10 SBIR/STTR records share this UEI (2003–2018). Reported award amounts total $6,779,434. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services